Adjuvant hormonal therapy for premenopausal breast cancer: incorporating clinical experience.

The article “Adjuvant Hormonal Therapy in Premenopausal Women With Operable Breast Cancer: Not-So-Peripheral Perspectives” by Richard Love, published in this issue of ONCOLOGY, raises a number of important practice issues in the setting of adjuvant hormonal therapy for premenopausal women. This paper was written partially in response to Dr. Pritchard’s publication, “Ovarian Suppression/Ablation in Premenopausal ER-Positive Breast Cancer Patients,” which appeared in the January 2009 issue of this journal.[1] We would like first to comment on the general differences between that article and Dr. Love’s current paper.